News|Articles|November 20, 2026

FDA Grants RMAT Designation to iSCIB1+ in Advanced Melanoma

Fact checked by: Ariana Pelosci

The FDA granted RMAT designation to inzitagene plasmivec for advanced melanoma ahead of a phase 3 trial expected to start in December 2026.

The FDA has granted regenerative medicine advanced therapy (RMAT) designation to inzitagene plasmivec (iSCIB1+), a needle-free DNA ImmunoBody vaccine, for the treatment of patients with advanced melanoma, according to a press release from Scancell Holdings plc.

The designation adds to the Fast Track designation previously granted to the agent and provides for closer engagement with the FDA, rolling review, and potential eligibility for priority review and accelerated approval. The drug’s developer plans to request an initial RMAT meeting with the agency to discuss the design of its phase 3 trial and manufacturing. The World Health Organization also recently agreed on inzitagene plasmivec as the International Nonproprietary Name for iSCIB1+.

The first patient is expected to be enrolled in the global, registrational phase 3 trial in December 2026, following FDA investigational new drug clearance and a UK Medicines and Healthcare products Regulatory Agency Clinical Trial Authorisation earlier this year.

“We are very encouraged by the progress across our pipeline,” Phillip L’Huillier, PhD, chief executive officer of Scancell, said in the press release. According to L’Huillier, the RMAT designation recognizes the potential of iSCIB1+ in advanced melanoma.

iSCIB1+ is administered intramuscularly without a needle and encodes an antibody that targets the melanoma-associated antigens gp100 and TRP-2.

Supporting Data From the Phase 2 SCOPE Trial

The designation is supported by data from the phase 2 SCOPE trial (NCT04079166) which is evaluating SCIB1 and iSCIB1+ in combination with checkpoint inhibitors in the first-line treatment of patients with advanced melanoma. As of a November 12, 2026, data cutoff, the 24-month overall survival (OS) rate was 82% among patients in the SCIB1 and iSCIB1+ cohorts (n = 80) and 87% among those who received iSCIB1+ alone.

In the HLA-target population, the 24-month progression-free survival (PFS) rate was 65% for the combined SCIB1 and iSCIB1+ cohorts and 71% for iSCIB1+ alone. The drug’s developer noted that the 24-month PFS rate reported with standard-of-care ipilimumab (Yervoy) plus nivolumab (Opdivo) in the phase 3 CheckMate 067 trial (NCT01844505) was 41.5%; this comparison is across trials and was not made head to head.

The complete response rate was 28% among patients treated with SCIB1 and iSCIB1+ (n = 80) and 31% in iSCIB1+ cohort 3. More mature PFS data and interim OS data are expected in the first half of 2027. The drug’s developer also plans to launch a phase 2 trial of iSCIB1+ monotherapy in the neoadjuvant/adjuvant melanoma setting in the first half of 2027.

Modi-1 Data in Renal Cell Carcinoma and Head and Neck Cancer

In the update, the drug’s developer also reported findings from the phase 2 ModiFY trial (NCT05329532) which is evaluating the Moditope vaccine Modi-1 in combination with checkpoint inhibitors in patients with renal cell carcinoma (RCC) and head and neck squamous cell carcinoma (HNSCC). Both cohorts have completed enrollment.

In the RCC cohort (n = 43), Modi-1 plus ipilimumab and nivolumab produced an objective response rate (ORR) of 48% and a median PFS of 7.8 months. Overall, 46% of patients mounted a vaccine-specific immune response to the citrullinated peptides in Modi-1.

Patients with a vaccine-specific immune response had a 6-month PFS rate of 75% vs 50% in those without a response (P = .0025). The ORR was 58% vs 36%, respectively, and the median PFS was not reached at 22 months of follow-up vs 6 months. Among immune responders, 59% received Modi-1ekv, a soluble, stable formulation given on an accelerated schedule; the 6-month PFS rate in this group was 90%.

Regarding safety, no toxicities beyond those expected with ipilimumab and nivolumab were observed, and there was no evidence of autoimmune disease.

In the HNSCC cohort, immune responders had a median PFS of 4.5 months vs 2.0 months in non-responders. This difference was not statistically significant and is considered exploratory.

Planned next steps for Modi-1 include RNA sequencing of immune responders to identify a predictive biomarker, study of isolated immune receptors, and potential evaluation in the neoadjuvant/adjuvant setting or in metastatic indolent tumors.

Reference

Scancell provides corporate and clinical update. News release. Scancell Holdings plc. November 19, 2026. Accessed November 20, 2026. https://tinyurl.com/5a3jd3rz


Related to this article